首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.
【24h】

Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation.

机译:供体和受体趋化因子受体CCR5基因型与骨髓移植后的存活相关。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite continual improvement, morbidity and mortality after hematopoietic stem cell transplantation (HSCT) remain high. The importance of chemokines in HSCT lies in their regulation of immune responses that determine transplantation outcomes. We investigated the role of recipient and donor chemokine system gene polymorphisms by using a candidate gene approach on the incidence of graft-versus-host disease and posttransplantation outcomes in 1370 extensively human leukocyte antigen-matched, unrelated donor-recipient pairs by using multivariate Cox regression models. Our analysis identified that recipients homozygous for a common CCR5 haplotype (H1/H1) had better disease-free survival (DFS; P = .005) and overall survival (P = .021). When the same genotype of both the donor and recipient were considered in the models, a highly significant association with DFS and overall survival was noted (P < .001 and P = .007, respectively) with absolute differences in survival of up to 20% seen between the groups at 3 years after transplantation (50% DFS for pairs with recipient CCR5 H1/H1 vs 30% for pairs with donor CCR5 H1/H1). This finding suggests that donor and/or recipient CCR5 genotypes may be associated with HSCT outcome and suggests new diagnostic and therapeutic strategies for optimizing therapy.
机译:尽管持续改善,造血干细胞移植(HSCT)后的发病率和死亡率仍然很高。 HSCT中趋化因子的重要性在于它们对决定移植结果的免疫反应的调节。我们通过使用候选基因方法,通过多变量Cox回归研究了候选基因方法对1370种广泛的人类白细胞抗原匹配,无关的供体-受体对的移植物抗宿主病发病率和移植后结局的发生率,研究了受体和供体趋化因子系统基因多态性的作用。楷模。我们的分析发现,对于普通CCR5单倍型(H1 / H1)纯合的接受者具有更好的无病生存期(DFS; P = .005)和总体生存期(P = .021)。当在模型中考虑供体和受体的基因型相同时,会发现与DFS和总体生存高度相关(分别为P <.001和P = .007),生存的绝对差异高达20%在移植后3年时在各组之间观察到(接受受体CCR5 H1 / H1的对为50%DFS,而施主CCR5 H1 / H1的对为30%)。这一发现表明供体和/或受体CCR5基因型可能与HSCT结果有关,并提出了优化治疗的新诊断和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号